The investment world is buzzing with the latest update on the Amanta Healthcare IPO, which has seen a remarkable response from investors across all categories. The initial public offering of the Ahmedabad-based pharmaceutical company, which specializes in sterile liquid formulations and medical devices, is a fresh issue of 1 crore equity shares, aiming to raise Rs 126 crore.
Since opening for subscription, the Amanta Healthcare IPO has garnered significant traction. The issue was fully subscribed within hours on its first day and continued to build momentum. On Day 2 of the bidding, the IPO was subscribed an impressive 19.60 times, with bids pouring in for 13.72 crore shares against the 70 lakh shares on offer.
The strong interest reflects a healthy appetite for the company's shares. Retail investors led the charge, with their portion being subscribed 23.31 times, showcasing robust confidence from individual bidders. The non-institutional investors' (NIIs) category also saw overwhelming demand, subscribing to 36.39 times their allocated quota. While Qualified Institutional Buyers (QIBs) started off slowly, their portion saw a significant rise in bids on the second day.
The price band for the Amanta Healthcare IPO has been set at Rs 120-126 per share. The company plans to use the proceeds to expand its manufacturing lines, including a new facility for Small Volume Parenterals (SVPs) and an expansion of its existing SteriPort line. These strategic investments are aimed at bolstering the company's manufacturing capacity and meeting the growing demand for its products, both domestically and internationally.
This robust subscription performance, combined with a positive grey market premium (GMP), indicates strong market sentiment and investor confidence in the company's future prospects. The final day of the Amanta Healthcare IPO subscription is today, September 3, and all eyes are on the final numbers as the bidding window closes. The allotment status is expected to be finalized on September 4, with a tentative listing date of September 9 on both the BSE and NSE.
Risk Disclaimer: Investing in IPOs is subject to market risks. The information in this article is for informational purposes only and should not be considered as financial advice. Investors are advised to conduct their own thorough research and consult with a qualified financial advisor before making any investment decisions. The performance of a company's shares after listing can be volatile and may not always reflect the initial investor sentiment.
